Hyderabad-based Bharat Biotech's Covid-19 vaccine, Covaxin, has equivalent immunogenicity against the Coronavirus variant discovered in the United Kingdom, a study by the Indian Council of Medical Research has found.
The scientists at ICMR's National Institute of Virology performed the plaque reduction neutralization test using sera collected from the 26 recipients of Bharat Biotech's Coronavirus vaccine (Covaxin) against UK-variant strain and circulating strains of SARS-COV-2 in India, reports Times of India.
"A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency dispel the uncertainty of possible neutralization escape," the ICMR study document published in pre-print server bioRxiv stated.
"We successfully isolated and characterized the SARS-CoV-2 from UK returnees in India with all signature mutations of the UK-variant," the document stated.
"We present the neutralizing antibodies (Nab) titers to underline the efficacy of Covaxin vaccine candidate against SARS-CoV-2 UK-variant and one of the heterologous strains. Sera collected from 38 vaccine recipients, who received Covaxin vaccine-candidate in phase-II trial had equivalent NAb titers to homologous strain and two heterologous strains with the characteristic substitution of the UK-variant," the study authors said.
"The median ratio of 50 per cent neutralization of sera was found to be 0.8 and 0.9 when compared with earlier detected SARS CoV-2 strains against mutant UK strain," they said.
"Our study evidently highlighted comparable neutralization activity of vaccinated individuals sera against variant as well as heterologous SARS-CoV-2 strains."
"Importantly, sera from the vaccine recipients could neutralise the UK-variant strains discounting the uncertainty around potential escape. It was reassuring from the neutralizing antibodies data generated in our laboratory that the indigenous Covaxin following its rollout in the vaccination program, could be expected to work against the new UK-variant. It is unlikely that the mutation would be able to dampen the potential benefits of the vaccine in concern," it said.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.